A glucokinase-activator (GKA) has received its first approval outside mainland China, marking a significant milestone in the management of Type 2 diabetes (T2D). This approval signifies a unique approach to T2D treatment. Hong Kong has been chosen by Hua Medicine as the springboard for their expansion into the international market. The decision was made public in Shanghai and Hong Kong on March 3, 2026.